Drugs / LX111
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07362927 | Mar 2026 → Sep 2027 expected | diabetic macular edema | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| Phase 0 | NCT07053358 | Jul 2025 → Nov 2026 expected | wet macular degeneration | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LX111 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07053358 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “LX111 Gene Therapy” NCT07053358 ↗ |
| Route | Intravitreal | “intravitreal injection of LX111” NCT07053358 ↗ |